Improving prostate brachytherapy quality assurance with MRI–CT fusion–based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancer

摘要: Abstract Purpose We combined sector analysis with MRI–CT fusion to comprehensively assess postimplant dosimetry after prostate brachytherapy. Methods and Materials Subjects were 50 men intermediate-risk cancer treated 125I brachytherapy in a prospective phase II clinical trial. On Day 30 the implantation, was evaluated base, midgland, apex regions on fused scans CT scans. Volumes of each receiving 100% prescribed dose (V100) doses 90% (D90) also calculated ultrasonogram used for treatment planning compared values derived from Results Fused revealed lower-than-expected whole (V100 = 91.3%, D90 = 152.9 Gy) (98.5% 183.6 Gy, p  Conclusions fusion–based feasible significantly lower base than estimated alone, although this did not affect biochemical outcomes. may be useful developing MRI-based dosimetric markers predict disease outcomes treatment-related morbidity.